TMCnet News
Notice of Annual General Meeting and Explanatory MemorandumSYDNEY, Australia, April 28, 2017 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (OTC:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Monday 29 May 2017 at 4:00 p.m. (Central Standard Time) and Tuesday 30 May 2017 at 7:00 a.m. (Australian Eastern Standard Time) NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on: Monday 29 May 2017 at 4:00 p.m. (Central Standard Time) and Tuesday 30 May 2017 at 7:00 a.m. (Australian Eastern Standard Time) Meeting to be held by teleconference (Dial-in details below):
//www.globenewswire.com/NewsRoom/AttachmentNg/9bf785e5-da8b-4b60-a5d2-d71ace68e95e ______________________ 26 April 2017 Dear Shareholder, On behalf of the Board of Directors of Parnell Pharmaceuticals Holdings Limited (ACN 137 904 413) (Company), I invite you to join us at our Annual General Meeting (AGM), which has been scheduled as follows:
Outline of the items of business At this AGM, we will provide an opportunity for shareholders to consider the following:
Details of these items are contained in the enclosed Notice of AM and Explanatory Memorandum. Voting at the AGM or by proxy A proxy form accompanies the enclosed Notice of AGM. If you wish to attend the AGM in person, please bring a copy of the proxy form with you. Registration will be available from 3:30 p.m. (CST). If you are unable to attend in person, I encourage you to appoint a proxy to vote on the resolutions contained in the Notice of AGM on your behalf, by completing and returning the enclosed proxy form. Details of how to submit the proxy form are included with the form. On behalf of all of the Directors, we look forward to hearing from you at the AGM. Yours sincerely, Alan Bell For more information, contact: Parnell Pharmaceuticals Holdings Robert Joseph, 913-274-2100 [email protected] Brad McCarthy, 913-274-2100 [email protected] |